Cara Therapeutics Investor Relations Material
Latest events
M&A Announcement
Cara Therapeutics
Q1 2025
13 May, 2025
Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cara Therapeutics Inc
Access all reports
Cara Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing therapies for pruritus and pain management. The company’s research centers on targeting peripheral kappa opioid receptors to treat itch and pain without central nervous system side effects. Cara Therapeutics serves the healthcare sector through research-driven pharmaceutical innovations. The company is headquartered in Stamford, Connecticut, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
CARA
Country
🇺🇸 United States